FibroGen, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2016. The filing identifies FibroGen, Inc. as the registrant; this differs from the company name in the request metadata. Unaudited consolidated financial statements.
Business context
FibroGen is a clinical-stage biopharmaceutical company. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD); pamrevlumab was in Phase 2 development across several indications, including idiopathic pulmonary fibrosis, pancreatic cancer and Duchenne muscular dystrophy. The company had no revenue from approved product sales; reported revenue came substantially from Astellas and AstraZeneca collaborations.
Financial results and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Total revenue | $30.1 million | $19.5 million | $147.7 million | $156.4 million |
| Operating expenses | $52.2 million | $63.3 million | $170.0 million | $185.6 million |
| Net loss | $24.2 million | $45.1 million | $27.7 million | $34.4 million |
| Net loss per share, basic and diluted | $0.38 | $0.74 | $0.44 | $0.57 |
| Cash provided by operating activities | Not presented for quarter | Not presented for quarter | $25.7 million | $20.7 million |
For the nine months, license and milestone revenue fell 13% year over year, while collaboration services revenue rose 36%. The revenue mix and timing of partner payments and milestones make reported revenue variable. Operating losses continued; margins are not meaningful as a measure of product economics given the development-stage business and collaboration revenue.
At September 30, 2016, cash and cash equivalents were $198.3 million and short- and long-term investments totaled $142.3 million. Including accounts receivable, these resources were approximately $348.2 million, excluding $7.3 million of restricted cash. Current assets were $253.5 million versus current liabilities of $61.7 million. Management said available cash, investments and receivables should cover anticipated cash requirements for at least 12 months.
Operating cash flow included substantial noncash stock-based compensation ($24.3 million) and a $14.7 million increase in deferred revenue; it should not be read as recurring cash generation from product sales. Lease financing obligations were $97.4 million at fair value (including current and long-term portions as disclosed in the notes); product development obligations were $15.7 million. The filing does not report conventional borrowings as a material debt item.
Material changes versus prior comparable periods
- Q3 revenue rose 54% and net loss narrowed, principally because FibroGen had reached its $116.5 million cap on initial roxadustat development funding outside China and was billing 100% of relevant development costs rather than 50%, alongside lower R&D expense.
- Nine-month revenue declined 6%, reflecting smaller AstraZeneca upfront and milestone payments in 2016 than in 2015; this was partly offset by higher reimbursable development activity after the funding cap was reached and a $10 million Astellas milestone.
- R&D expense fell 11% for the nine months, mainly from reduced outside services and partner-cost reimbursements, partly offset by higher clinical-trial, employee, drug-development and stock-compensation costs. G&A rose 7%.
- Cash and cash equivalents increased $45.0 million from year-end 2015. Total cash, investments and receivables were about $19.9 million higher than at year-end, per management.
Outlook, commentary and risks
- Management expected continued operating losses and increasing R&D spending as programs advanced, while stating available resources should fund operations for at least the next 12 months. The company may need additional financing; no assurance was given it would be available on acceptable terms.
- Management anticipated a U.S. roxadustat NDA filing in 2018. China Phase 3 enrollment was complete; it expected topline data in early 2017, 52-week safety data in Q2 2017, and a China submission in Q2 or Q3 2017. These are forward-looking plans, not guarantees.
- For pamrevlumab, the company expected topline results from the IPF Phase 2 study in mid-2017 and completion of enrollment in its combination sub-study by year-end 2016. Enrollment continued in pancreatic cancer and DMD studies.
- AstraZeneca approved development of roxadustat for MDS in September 2016. FibroGen extended the estimated AstraZeneca joint-development service period through 2020 from 2018, leaving an additional $7.1 million of deferred revenue classified as non-current.
- Key risks include clinical efficacy and safety outcomes, regulatory approval and timing, manufacturing capacity and quality, reliance on collaboration partners and third-party suppliers, reimbursement and competition, and the need for further capital. The company reported no material legal proceedings.
- GlaxoSmithKline filed inter partes review petitions challenging six FibroGen U.S. patents on September 30, 2016. FibroGen said the outcome was unpredictable and believed the challenged patents would withstand review; it stated the challenges did not threaten roxadustat exclusivity or freedom to operate. A separate appeal concerning a European roxadustat patent remained pending.
- Q3 included an immaterial $2.2 million out-of-period reversal of previously overstated operating expenses; the filing says it had no impact on nine-month financial statements. The 2015 comparative cash-flow presentation also included a nonmaterial correction relating to an $8.5 million cash/investment classification.
Important facts for investors to verify
- Clinical-trial progress, safety and efficacy data, regulatory milestones and whether stated submission timelines are achieved.
- Cash burn and the sustainability of operating cash flow, particularly its dependence on deferred revenue, noncash compensation and collaboration funding.
- Continuity and terms of Astellas and AstraZeneca collaborations, cost-sharing arrangements, milestones and any partner termination or reprioritization.
- Outcome and commercial significance of the U.S. patent reviews and European patent appeal.
- Manufacturing readiness, future financing needs and whether the stated 12-month liquidity outlook remains supportable.